Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients

ABSTRACT Significant liver fibrosis is an indication for antiviral therapy in chronic hepatitis B (CHB). Using liver histology assessed by Scheuer system, we evaluated the diagnostic performance of PRO‐C3, GP73, and their combination for the presence of liver fibrosis, and compared them with FIB‐4,...

Full description

Saved in:
Bibliographic Details
Main Authors: Qianqian Chen, Ming‐Hua Zheng, Li Zhu, Fajuan Rui, Wenjing Ni, Yali Xiong, Xinyu Hu, Rahma Issa, Yixuan Zhu, Leyao Jia, Scott Barnett, Shengxia Yin, Chuanwu Zhu, Chao Wu, Mindie H. Nguyen, Jie Li
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:MedComm
Subjects:
Online Access:https://doi.org/10.1002/mco2.70236
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850038483952861184
author Qianqian Chen
Ming‐Hua Zheng
Li Zhu
Fajuan Rui
Wenjing Ni
Yali Xiong
Xinyu Hu
Rahma Issa
Yixuan Zhu
Leyao Jia
Scott Barnett
Shengxia Yin
Chuanwu Zhu
Chao Wu
Mindie H. Nguyen
Jie Li
author_facet Qianqian Chen
Ming‐Hua Zheng
Li Zhu
Fajuan Rui
Wenjing Ni
Yali Xiong
Xinyu Hu
Rahma Issa
Yixuan Zhu
Leyao Jia
Scott Barnett
Shengxia Yin
Chuanwu Zhu
Chao Wu
Mindie H. Nguyen
Jie Li
author_sort Qianqian Chen
collection DOAJ
description ABSTRACT Significant liver fibrosis is an indication for antiviral therapy in chronic hepatitis B (CHB). Using liver histology assessed by Scheuer system, we evaluated the diagnostic performance of PRO‐C3, GP73, and their combination for the presence of liver fibrosis, and compared them with FIB‐4, APRI, Agile 3+, FAST, and LSM in treatment‐naïve CHB patients from two centers. The study included 324 patients, of whom 167 had S2–4 (significant fibrosis) and 83 had S3–4 (advanced fibrosis). PRO‐C3 levels were higher in those with S2–4 and S3–4 compared with S0–1 and S0–2 (both p < 0.001), with similar findings for GP73. PRO‐C3 and GP73 were independently associated with S2–4 and S3–4 in multivariable analyses. The area under the curves (AUCs) of PRO‐C3 for S2–4 and S3–4 were 0.81 and 0.80, respectively, and exceeded those of GP73 (0.75 and 0.73). The combination of PRO‐C3 and GP73 also had significantly higher AUCs for both S2–4 (0.84 vs. 0.64) and S3–4 (0.80 vs. 0.65) as compared with FIB‐4, with similar findings for APRI, GP73, LSM, FAST, and Agile 3+ for S2–4. In conclusion, PRO‐C3 alone or in combination with GP73 is highly predictive for detecting significant liver fibrosis among CHB patients.
format Article
id doaj-art-9c4f058c4ebf4cb19db02e512b4ab355
institution DOAJ
issn 2688-2663
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series MedComm
spelling doaj-art-9c4f058c4ebf4cb19db02e512b4ab3552025-08-20T02:56:34ZengWileyMedComm2688-26632025-06-0166n/an/a10.1002/mco2.70236Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B PatientsQianqian Chen0Ming‐Hua Zheng1Li Zhu2Fajuan Rui3Wenjing Ni4Yali Xiong5Xinyu Hu6Rahma Issa7Yixuan Zhu8Leyao Jia9Scott Barnett10Shengxia Yin11Chuanwu Zhu12Chao Wu13Mindie H. Nguyen14Jie Li15Department of Infectious DiseasesNanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineNanjingJiangsuChinaMAFLD Research CenterDepartment of Hepatologythe First Affiliated Hospital of Wenzhou Medical UniversityWenzhou Zhejiang ChinaDepartment of Hepatologythe Fifth People's Hospital of SuzhouSuzhouJiangsuChinaDepartment of Infectious DiseasesNanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineNanjingJiangsuChinaDepartment of Infectious DiseasesNanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineNanjingJiangsuChinaDepartment of Infectious DiseaseNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChinaDepartment of Infectious DiseaseNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChinaDepartment of Infectious DiseaseNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChinaDepartment of Infectious DiseaseNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChinaDepartment of Infectious DiseasesNanjing Drum Tower Hospital Clinical College of Nanjing Medical UniversityNanjingJiangsuChinaDivision of Gastroenterology and HepatologyStanford University Medical CenterPalo AltoCaliforniaUSADepartment of Infectious DiseaseNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChinaDepartment of Hepatologythe Fifth People's Hospital of SuzhouSuzhouJiangsuChinaDepartment of Infectious DiseaseNanjing Drum Tower HospitalAffiliated Hospital of Medical SchoolNanjing UniversityNanjingJiangsuChinaDivision of Gastroenterology and HepatologyStanford University Medical CenterPalo AltoCaliforniaUSADepartment of Infectious DiseasesNanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineNanjingJiangsuChinaABSTRACT Significant liver fibrosis is an indication for antiviral therapy in chronic hepatitis B (CHB). Using liver histology assessed by Scheuer system, we evaluated the diagnostic performance of PRO‐C3, GP73, and their combination for the presence of liver fibrosis, and compared them with FIB‐4, APRI, Agile 3+, FAST, and LSM in treatment‐naïve CHB patients from two centers. The study included 324 patients, of whom 167 had S2–4 (significant fibrosis) and 83 had S3–4 (advanced fibrosis). PRO‐C3 levels were higher in those with S2–4 and S3–4 compared with S0–1 and S0–2 (both p < 0.001), with similar findings for GP73. PRO‐C3 and GP73 were independently associated with S2–4 and S3–4 in multivariable analyses. The area under the curves (AUCs) of PRO‐C3 for S2–4 and S3–4 were 0.81 and 0.80, respectively, and exceeded those of GP73 (0.75 and 0.73). The combination of PRO‐C3 and GP73 also had significantly higher AUCs for both S2–4 (0.84 vs. 0.64) and S3–4 (0.80 vs. 0.65) as compared with FIB‐4, with similar findings for APRI, GP73, LSM, FAST, and Agile 3+ for S2–4. In conclusion, PRO‐C3 alone or in combination with GP73 is highly predictive for detecting significant liver fibrosis among CHB patients.https://doi.org/10.1002/mco2.70236biomarkerchronic hepatitis BGolgi protein 73liver fibrosisN‐terminal propeptide of type III collagen
spellingShingle Qianqian Chen
Ming‐Hua Zheng
Li Zhu
Fajuan Rui
Wenjing Ni
Yali Xiong
Xinyu Hu
Rahma Issa
Yixuan Zhu
Leyao Jia
Scott Barnett
Shengxia Yin
Chuanwu Zhu
Chao Wu
Mindie H. Nguyen
Jie Li
Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients
MedComm
biomarker
chronic hepatitis B
Golgi protein 73
liver fibrosis
N‐terminal propeptide of type III collagen
title Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients
title_full Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients
title_fullStr Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients
title_full_unstemmed Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients
title_short Superior Diagnostic Efficacy of N‐Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients
title_sort superior diagnostic efficacy of n terminal propeptide of type iii collagen and golgi protein 73 for detection of fibrosis in chronic hepatitis b patients
topic biomarker
chronic hepatitis B
Golgi protein 73
liver fibrosis
N‐terminal propeptide of type III collagen
url https://doi.org/10.1002/mco2.70236
work_keys_str_mv AT qianqianchen superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT minghuazheng superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT lizhu superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT fajuanrui superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT wenjingni superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT yalixiong superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT xinyuhu superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT rahmaissa superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT yixuanzhu superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT leyaojia superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT scottbarnett superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT shengxiayin superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT chuanwuzhu superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT chaowu superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT mindiehnguyen superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients
AT jieli superiordiagnosticefficacyofnterminalpropeptideoftypeiiicollagenandgolgiprotein73fordetectionoffibrosisinchronichepatitisbpatients